- University of Pittsburgh, PhD, 2024
- Austin College, BA, 2019
Education & Training
Hu D, Lyu X, Li Z, Ekambaram P, Dongre A, Freeman T, Joy M, Atkinson JM, Brown DD, Cai Z, Carleton NM, Crentsil HE, Little J 4th, Kemp F, Klei LR, Beecher M, Sperinde J, Huang W, Joensuu H, Srinivasan A, Pogue-Geile KL, Wang Y, Feng H, Eli LD, Lalani AS, Zou J, Tseng GC, Bruno TC, Lee AV, Oesterreich S, Wolmark N, Allegra CJ, Jacobs SA, McAllister-Lucas LM, Lucas PC. p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2+ breast cancer that limits trastuzumab deruxtecan efficacy. Nat Cancer. 2025 Jul;6(7):1202-1222. doi: 10.1038/s43018-025-00969-4. Epub 2025 Jun 27. PMID: 40579589.
Crentsil HE, Felker J. Resolution of Ascites Following Targeted Therapy in a Pediatric Patient With BRAF V600E-Mutant Low-Grade Glioma. Pediatr Blood Cancer. 2025 Mar;72(3):e31480. doi: 10.1002/pbc.31480. Epub 2024 Dec 9. PMID: 39654056.
Azambuja JH, Yerneni SS, Maurer LM, Crentsil HE, Debom GN, Klei L, Smyers M, Sneiderman CT, Schwab KE, Acharya R, Wu YL, Ekambaram P, Hu D, Gough PJ, Bertin J, Melnick A, Kohanbash G, Bao R, Lucas PC, McAllister-Lucas LM. MALT1 protease inhibition restrains glioblastoma progression by reversing tumor-associated macrophage-dependent immunosuppression. bioRxiv [Preprint]. 2024 Sep 27:2024.09.26.614808. doi: 10.1101/2024.09.26.614808. PMID: 39386586; PMCID: PMC11463364.
MALT1 protease as a regulator of anti-tumor immunity and tumor progression in H3K27M Diffuse Midline Glioma